bioRxivCancer BiologyPreprint
POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer
Wungki ParkiD, Shigeaki UmedaiD, Marc HilmiiD, Catherine Anne O'ConnoriD, Roshan SharmaiD, Nuray TezcaniD, Haochen ZhangiD, Yingjie ZhuiD, Carly SchwartziD, Amin YaqubieiD, Anna M. VargheseiD, Kevin SoaresiD, Vaia FlorouiD, DaeWon Kim, Steven Brad MaroniD, Guillem ArgilésiD, Fiyinfolu O. BaloguniD, Caitlin A. McIntyreiD, Daehee KimiD, Kenneth H. YuiD, Joanne F. ChouiD, Akimasa HayashiiD, Fergus KeaneiD, Danny N. KhaliliD, Walid Khaled ChatilaiD, , Eileen Mary O'ReillyiD
Abstract
Pancreatic cancer (PC) is broadly resistant to immune checkpoint blockade, although a subset of homologous recombination-deficient (HRD) tumors exhibits durable immune engagement. The genomic features that distinguish these immune-responsive tumors from immune-inert HRD tumors remain poorly understood. Here we identify a microhomology-mediated end joining (MMEJ) repair scar, the MMEJ Deletion Footprint (MDF), as a genomic readout of POLQ-associated error-prone repair that enriches for frameshift indels. Across the multi-omic discovery cohort integrating tumor genomics, single-nucleus transcriptomics and spatial immune profiling, MDF-high HRD PC exhibited increased frameshift-indel-derived neoantigens and interferon programs. MDF was further associated with remodeling of the myeloid compartment toward MHC II-high dendritic cell-like antigen-presenting macrophage states and the immune synapse architecture marked by increased spatial interaction between APC-like macrophages and cytotoxic CD8+ T cells. These tissue-level features aligned with a functional trajectory shift of CD8+ T cells, consistent with effective anti-tumor immunity and was associated with favorable clinical outcomes of patients. Together, our findings position MMEJ-linked repair scarring as actionable biology that connects an HRD genotype to immune organization and suggests rational immunotherapy combinations that may enhance antigen presentation and myeloid activation to extend durable benefit in HRD-lineage cancers.
- organism: human
- assay: bulk RNA-seq
- assay: spatial transcriptomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: cell-cell communication
- approach: statistical model
- approach: machine learning (classical)
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Neoantigen-reactive CD8+ T cell engagement marks exceptional survivors of pancreatic cancer
Marc Hilmi, Joshua David Schoenfeld, … Wungki Park·bioRxiv·Sep 18, 2026
- Coordinated macrophage and T cell interactions mediate response to checkpoint blockade in colorectal cancer.
Guillaume Mestrallet, Matthew Brown, … Nina Bhardwaj·Cell Reports MedicinePeer-reviewed·May 1, 2026
- Antigen-presenting type-I conventional dendritic cells facilitate curative checkpoint blockade immunotherapy in pancreatic cancer
K. K. Mahadevan, A. M. Dyevoich, … R. Kalluri·bioRxiv·Mar 5, 2023
- Tumor-intrinsic MHC-II activation in pancreatic ductal adenocarcinoma enhances immune response and treatment efficacy
Canping Chen, Kyle P. Gribbin, … Zheng Xia·bioRxiv·Oct 21, 2025
- Macrophage-derived granulin drives resistance to immune checkpoint inhibition in metastatic pancreatic cancer
V. Quaranta, C. Rainer, … M. Schmid·bioRxiv·Dec 15, 2017
- Post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinoma
Yifei Guo, Jennifer M. Finan, … Robert L Eil·Journal for ImmunoTherapy of CancerPeer-reviewed·Nov 1, 2025